[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579257":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":11,"studyPopulation":11,"armGroups":25,"interventions":42,"overallOfficials":11,"centralContacts":77,"locations":83,"responsibleParty":110,"collaborators":11,"id":112,"slug":11,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":11,"eligibilityCriteria":117,"healthyVolunteers":113,"sex":118,"minAge":119,"maxAge":11,"enrollmentInfo":120,"targetDuration":11,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":11,"overallStatus":86,"whyStopped":11,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"The mean change of PANSS(Positive and Negative Syndrome Scale) total score",null,"1, 2, 3, 5, 9 weeks from baseline(Visit 2)",{"measure":14,"description":11,"timeFrame":15},"Incidence of treatment-emergent adverse events","From the administration of investigational products prescribed at baseline(Visit 2) to 11 weeks(Visit 8)",{"allocation":17,"interventionModel":18,"interventionModelDescription":11,"primaryPurpose":19,"observationalModel":11,"timePerspective":11,"maskingInfo":20},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":21,"maskingDescription":11,"whoMasked":22},"DOUBLE",[23,24],"PARTICIPANT","INVESTIGATOR",[26,36],{"label":27,"type":28,"description":11,"interventionNames":29},"Gradual titration group","EXPERIMENTAL",[30,31,32,33,34,35],"Drug: BR5402A","Drug: BR5402B","Drug: BR5402C","Drug: BR5402C-1","Drug: BR5402D","Drug: BR5402D-1",{"label":37,"type":38,"description":11,"interventionNames":39},"Conventional titration group","ACTIVE_COMPARATOR",[40,41,32,33,34],"Drug: BR5402A-1","Drug: BR5402B-1",[43,48,53,56,61,64,69,72],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":11},"DRUG","BR5402A","Subjects take the investigational products once a day",[27],{"type":44,"name":49,"description":46,"armGroupLabels":50,"otherNames":51},"BR5402A-1",[37],[52],"Placebo of BR5402A",{"type":44,"name":54,"description":46,"armGroupLabels":55,"otherNames":11},"BR5402B",[27],{"type":44,"name":57,"description":46,"armGroupLabels":58,"otherNames":59},"BR5402B-1",[37],[60],"Placebo of BR5402B",{"type":44,"name":62,"description":46,"armGroupLabels":63,"otherNames":11},"BR5402C",[37,27],{"type":44,"name":65,"description":46,"armGroupLabels":66,"otherNames":67},"BR5402C-1",[37,27],[68],"Placebo of BR5402C",{"type":44,"name":70,"description":46,"armGroupLabels":71,"otherNames":11},"BR5402D",[37,27],{"type":44,"name":73,"description":46,"armGroupLabels":74,"otherNames":75},"BR5402D-1",[27],[76],"Placebo of BR5402D",[78],{"name":79,"role":80,"phone":81,"phoneExt":11,"email":82},"Shin-young Oh","CONTACT","+82+2-708-8000","syoh@boryung.co.kr",[84,98],{"facility":85,"status":86,"city":87,"state":11,"zip":11,"country":88,"countryCode":11,"cosmosGeoPoint":89,"geoPoint":94,"contacts":95},"Kyungbook National university hospital","RECRUITING","Daegu","South Korea",{"type":90,"coordinates":91},"Point",[92,93],128.59111,35.87028,{"lat":93,"lon":92},[96],{"name":97,"role":80,"phone":11,"phoneExt":11,"email":11},"Seung-hee Won",{"facility":99,"status":100,"city":101,"state":11,"zip":11,"country":88,"countryCode":11,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Hanyang University Guri Hospital","NOT_YET_RECRUITING","Guri-si",{"type":90,"coordinates":103},[104,105],127.1394,37.5986,{"lat":105,"lon":104},[108],{"name":109,"role":80,"phone":11,"phoneExt":11,"email":11},"JoonHo Choi",{"type":111,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100579257",false,"NCT06821945","A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia","A Multi-Center, Randomized, Double-Blind, Parallel-Design, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia","Inclusion Criteria:\n\n* Of patients with schizophrenia in accordance with DSM(Diagnostic and Statistical Manual of Mental Disorders)-5 diagnostic criteria, who are judged that administration of low dose is more appropriate than initial recommended dose or standard titration dose of olanzapine to consider medical conditions by investigator\n* Patients with the duration of schizophrenia for more than 1 year at screening visit(Visit 1)\n\nExclusion Criteria:\n\n* Patients diagnosed schizophrenia spectrum and other psychotic disorder(e.g. schizoaffective disorder, etc.), bipolar disorder, depressive disorder, etc., in accordance with DSM(Diagnostic and Statistical Manual of Mental Disorders)-5 diagnostic criteria at screening visit(Visit 1)\n* Patients with a history of hospitalization for worsening schizophrenia within 12 weeks at screening visit(Visit 1)","ALL","19 Years",{"count":121,"type":122},120,"ESTIMATED","INTERVENTIONAL",[125],"PHASE2","The objective of this clinical trial is to evaluate the safety and efficacy of olanzapine titration schedule in patients with schizophrenia",[128],"Schizophrenia","2025-09-11",{"date":131,"type":132},"2025-09-15","ACTUAL",{"date":134,"type":132},"2025-05-30",{"date":136,"type":122},"2027-05",{"name":5,"class":6},2]